DOI: 10.1177/15578100261472246 ISSN: 1536-2310
LIMK1
and
PKM
as Integratively Identified Transcriptomic Signatures in Inflammatory Bowel Disease
Houshu Tu, Menglin Chen, Panpan Zhu, Ling He, Jing Hong
Inflammatory bowel disease (IBD) involves complex immunometabolic dysregulation. Mitochondria-associated endoplasmic reticulum membranes (MAMs) link metabolic adaptation and inflammatory signaling, but gene expression features associated with MAM-related transcriptomic states in IBD remain unclear. Public transcriptomic datasets were integrated with a curated MAM-related gene set and herbal target information. Differential expression analysis, weighted gene coexpression network analysis, and machine learning-assisted feature selection were used to identify candidate genes. A two-gene nomogram was constructed and evaluated in discovery and independent validation datasets. Functional enrichment, immune deconvolution, regulatory network prediction, molecular docking, 200-ns molecular dynamics simulations, and preliminary quantitative polymerase chain reaction validation were performed.
LIMK1
and
PKM
were identified as candidate transcriptomic signature genes associated with IBD status and MAM-related transcriptional states, showing discriminatory performance in independent datasets. Both genes were associated with cytokine–cytokine receptor interaction and drug metabolism–cytochrome P450 pathways and were linked to macrophage-related immune states. Structural analyses suggested stable predicted binding between
PKM
and 1-(4-hydroxybenzyl)-4-methoxy-9,10-dihydrophenanthrene-2,7-diol and structurally plausible interactions between
LIMK1
and palmatine. Preliminary tissue-level validation supported the disease-associated expression pattern of
PKM
, whereas
LIMK1
showed a consistent but nonsignificant upward trend.
LIMK1
and
PKM
may represent candidate transcriptomic signatures associated with MAM-related regulatory states in IBD. These findings should be interpreted as hypothesis-generating associations rather than evidence of MAM localization, functional causality, or therapeutic efficacy. Further protein-level and functional validation is required.